Hasil Pencarian - Polonis V

  • Menampilkan 1 - 5 hasil dari 5
Perbaiki Hasil
  1. 1
    P19-41. Full-length IMC expressing Renilla luciferase for neutralization assay using PBMC

    P19-41. Full-length IMC expressing Renilla luciferase for neutralization assay using PBMC oleh Polonis V, Kim J, Wieczorek L, Sanders-Buell E, Chenine A, Tovanabutra S

    Diterbitkan 2009-10-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Soluble and bacteriophage T4 displayed gp41 mutant proteins as HIV-1 vaccine candidates

    Soluble and bacteriophage T4 displayed gp41 mutant proteins as HIV-1 vaccine candidates oleh Gao G, Peachman KK, Wieczorek L, Polonis V, Alving CR, Rao M, Rao VB

    Diterbitkan 2012-09-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    P04-18. Comparison of HIV neutralization assays for use in vaccine research and clinical trials, phase II: results from the NeutNet working group

    P04-18. Comparison of HIV neutralization assays for use in vaccine research and clinical trials, phase II: results from the NeutNet working group oleh Polonis V, Osmanov S, Morris L, Moog C, Montefiori D, Malnati M, Lopalco L, Jansson M, Holmes H, Heyndrickx L, Heath A, Fenyö E, Bongertz V, Alcami J, Scarlatti G, Ramaswamy M, Sattentau Q, Schuitemaker H, Wrin T

    Diterbitkan 2009-10-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Antigenicity and immunogenicity of a novel, acute HIV-1 Tanzanian subtype C gp145 envelope protein for clinical development

    Antigenicity and immunogenicity of a novel, acute HIV-1 Tanzanian subtype C gp145 envelope protein for clinical development oleh Polonis V, Wieczorek L, Kalyanaraman V, Matyas G, Whitney S, Williams C, Tovanabutra S, Sanders-Buell E, Wesberry M, Ochsenbauer C, Chenine A, Rao M, Tong T, Alving C, Cheng H, Zolla-Pazner S, Michael N, VanCott T, Marovich M

    Diterbitkan 2012-09-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Passive immunization with polyclonal anti-SHIV IgG: partial protection or increased acquisition of heterologous tier 2 SHIV – depending on IgG dose

    Passive immunization with polyclonal anti-SHIV IgG: partial protection or increased acquisition of heterologous tier 2 SHIV – depending on IgG dose oleh Sholukh AM, Siddappa NB, Shanmuganathan V, Lakhashe SK, Rasmussen RA, Watkins JD, Vyas HK, Mukhtar MM, Hemashettar G, Thorat S, Yoon JK, Villinger F, Novembre FJ, Landucci G, Forthal DN, Ratcliffe S, Robert-Guroff M, Polonis V, Montefiori DC, Ertl HC, Ruprecht RM

    Diterbitkan 2012-09-01
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: